Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Parallel, Randomized, Multi-center Study to Evaluate the Safety and Immunogenicity of Different LNP Formulations of mRNA Vaccines Using the RSV Monovalent Antigen in Healthy Participants 18 to 49 Years of Age

NCT07071558 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07071558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07071558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Parallel, Randomized, Multi-center Study to Evaluate the Safety and Immunogenicity of Different LNP Formulations of mRNA Vaccines Using the RSV Monovalent Antigen in Healthy Participants 18 to 49 Years of Age
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Completed
Start date
July 14, 2025
Completion date
March 17, 2026
Enrollment
240 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus immunization